QIAGEN NV (QIA BE) stock market data APIs
€40.9286
0(0%)
as of February 5, 2026
Try our APIs with
free plan!
QIAGEN NV Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for QIA.BE.
Prev. Close
40.9286
Open
40.9286
High
40.9286
Low
40.9286
52 wk Range
33.1998-44.0974
Market Cap
10 941 M
Dividends (Yield)
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get QIAGEN NV data using free add-ons & libraries
Get QIAGEN NV Fundamental Data
QIAGEN NV Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: 0.53
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
QIAGEN NV News
New
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 VENLO, Netherlands,...
Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 82%
Key Insights Significantly high institutional ownership implies Qiagen's stock price is sensitive to their trading actions A total of 13 investors have a majority stake in the company with 51% owners...
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
Return of approximately $500 million – maximum approved by shareholders – set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase – combines a f...
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
